Sorrento Therapeutics Inc (SRNE)

[dia76ca]

TEN January/February potential milestone news items
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. They announced partnering intentions about 7 months ago! And look to the partnership partners to become the eventual buyout actors. Remember the Genentech/Roche scenario!
2. SCILEX SPINOFF. More SEMDEXA data is due in January. This new treatment could gross $6-10 billion annually in the US alone!. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales have recorded in Q4 of 2021 and are ramping up in Q1 of 2022. Mexico leads the way and Europe, Central and South America, Canada, Japan and the US will follow. 30 million monthly test production near term! And now they have acquired a new technology which can produce new tests at one tenth the cost!
4. COVIDROPS, COVI-MSC, COVISHIELD, SEMDEXA, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. COVIDROPS is in phase 2 in the US and UK. Soon to enter a pediatric trial in Mexico. An Interim analysis of the UK out-patient trial is expected in Jan/Feb.
6. COVI-MSC is in phase 2 trials in the US and Brazil The Brazilian study is pivotal. In Brazil it is now followed by a trial for long-haul Covid patients.
7. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). A prestigious European journal made it front page news. This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
8. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). An allogenic DAR-T, an anti-TROP2 ADC and a second generation oncolytic virus(Seprehvec) will enter the clinic as well as several additional ADNAB(Mayo Clinic) drugs.
9. Non-opioid RTX is in phase 2 for arthritic knee pain and will enter phase 2 for epidural delivery for severe cancer pain in Q1.
10. Sofusa will report on a phase 1 arthritis treatment in Q1. Meanwhile it is being tested in delivering cancer therapies including a collaboration with the Mayo Clinic to test lymphatic delivery.
And have a look at the top 34 portfolio items from the SRNE website. No wonder Blackrock holds over 20 million shares!
https://sorrentotherapeutics.com/research/pipeline/